trending Market Intelligence /marketintelligence/en/news-insights/trending/b664Y-dy7fkAt9bBPkIDZQ2 content esgSubNav
In This List

Sesen Bio begins US FDA application process for bladder cancer drug

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


Sesen Bio begins US FDA application process for bladder cancer drug

Sesen Bio Inc. has initiated the submission of bladder cancer drug Vicinum to the U.S. Food and Drug Administration for approval.

The Cambridge, Mass.-based company expects to complete the rolling submissions process by 2020. Sesen plans to request a priority review if the FDA accepts the application.

Vicinum, which treats high-grade, non-muscle-invasive bladder cancer, was granted fast-track designation from the U.S. regulator in 2018. The drug removed detectable cancer in 39% to 80% of patients in a late-stage clinical trial, according to results issued in May 2018.